00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
15:03 , May 25, 2018 |  BC Week In Review  |  Clinical News

FDA accepts NDA for Cosmo's antibiotic

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo (Rifamycin SV MMX) to treat travelers’ diarrhea. The PDUFA date is Nov. 16. Aemcolo is a broad-spectrum, semisynthetic, oral...
20:21 , May 18, 2018 |  BC Extra  |  Company News

FDA accepts NDA for Cosmo's antibiotic

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted and granted Priority Review to an NDA for Aemcolo (Rifamycin SV MMX) to treat travelers’ diarrhea. The PDUFA date is Nov. 16. Aemcolo is a broad-spectrum, semisynthetic, oral...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Rifamycin SV MMX: Phase III data

A double-blind, international Phase III trial in over 800 patients with travelers’ diarrhea showed that twice-daily 400 mg oral Rifamycin SV MMX for 3 days met the primary endpoint of non-inferiority to ciprofloxacin in improving...
01:58 , Oct 4, 2014 |  BC Extra  |  Top Story

Salix, Cosmo abandon merger

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) and Cosmo Pharmaceuticals S.p.A. (SIX:COPN) said they have ended their merger agreement. The two companies had envisioned financial benefits from domiciling the combined entity in Ireland. Under the July agreement, Salix...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Salix Pharmaceuticals Ltd, Cosmo deal

Salix will merge with an Irish subsidiary of partner Cosmo in a stock deal that will give Cosmo about a 20% stake in Salix. Salix will become a subsidiary of the Irish subsidiary, Cosmo Technologies...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) was down $0.96 to $10.54 last week after partner Gruenenthal Group submitted an MAA to EMA for Zalviso to treat moderate to severe acute pain. The submission triggered a...
01:34 , Jul 10, 2014 |  BC Extra  |  Company News

Salix, Cosmo subsidiary to merge

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) will merge with an Irish subsidiary of partner Cosmo Pharmaceuticals S.p.A. (SIX:COPN) in a stock deal that will give Cosmo about a 20% stake in Salix. Salix will become a subsidiary...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

Cosmo drug delivery, gastrointestinal news

Cosmo said it will separate its chairman and CEO roles, effective March 27. Mauro Ajani, currently chairman and CEO, will focus on his role as chairman. Alessandro Della Cha, Cosmo's legal counsel and a director,...